Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention

Fig. 1

In vitro generation and characterization of allogenic HSC-engineered iNKT (AlloHSC-iNKT) cells. a Experimental design to generate AlloHSC-iNKT cells in vitro. CB cord blood, HSC hematopoietic stem cell, SG suicide gene, Lenti/iNKT-SG lentiviral vector encoding an iNKT TCR gene and a suicide gene, ATO artificial thymic organoid. b Generation of iNKT cells (identified as iNKT TCR+CD3+ cells) during ATO culture. A 6B11 monoclonal antibody was used to stain iNKT TCR. c Generation of iNKT cells (identified as iNKT TCR+CD3+ cells) during Feeder-free culture. d Yields of AlloHSC-iNKT cells generated from ATO and Feeder-free cultures. e FACS characterization of surface marker expression and intracellular cytokine and cytotoxic molecule production of AlloHSC-iNKT cells. Periphery blood mononuclear cell (PBMC)-derived iNKT (PBMC-iNKT) cells and conventional αβ T (PBMC-Tc) cells were included as controls. Representative of over 5 experiments

Back to article page